TY - JOUR
T1 - N-Methylformamide in advanced squamous cancer of the uterine cervix
T2 - An Eastern Cooperative Oncology Group phase II trial
AU - Rajdev, Lakshmi
AU - Yu, Zi Fan
AU - Wadler, Scott
AU - Weller, Edie
AU - Kahn, S. Benham
AU - Tormey, Douglass
AU - Skeel, Roland
AU - Wiernik, Peter H.
N1 - Funding Information:
This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair) and supported in part by Public Health Service grants CA 14958, CA 23318, CA 21076, CA 66636, CA 21115 from the National Cancer Institute, National Institute of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institutes.
PY - 2001
Y1 - 2001
N2 - Purpose: Preclinical and clinical data support the study of polar-planar compounds such as N-Methylformamide (NMF) in advanced squamous cell carcinoma of the uterine cervix (SCC). This phase II trial sought to determine the efficacy and toxicities of NMF in patients with advanced SCC. Patients and methods: Eligibility for this trial required bidimensionally measurable squamous or adenosquamous cell cancer of the uterine cervix incurable by surgery or radiation therapy, ECOG performance status of ≤2, no prior NMF and no more than one prior chemotherapy regimen. Patients received NMF at 2000 mg/m 2 intravenously over 15-30 minutes days 1, 8 and 15. The cycle was repeated every 42 days. A single dose escalation of 25%, 500 mg/m 2 was made after the first cycle if the toxicities did not exceed grade I for hepatic toxicity and grade II for nausea and vomiting. Results: From July 1987 through September 1998, 21 patients with advanced squamous cell carcinoma of the uterine cervix were entered on study. Two patients were ineligible because there was no pretreatment SGOT on one and the other deteriorated prior to drug approval. Therefore, 19 patients were include in the analysis of response and survival. Four were inevaluable, three due to inappropriate tumor evaluation and one secondary to grade III vomiting, who went off study. These patients were included in the denominator while computing the results. There were 2 deaths, one due to pulmonary hemorrhage from perforation during central venous insertion and one due to disease. 30% (6/19) patients had toxicities, Eastern Cooperative Oncology Group (ECOG) grade III or higher and 2 of these patients suffered multiple grade III toxicities. There were no complete or partial responses. Conclusion: In this population, NMF in the dose and schedule employed exhibited no clinical activity.
AB - Purpose: Preclinical and clinical data support the study of polar-planar compounds such as N-Methylformamide (NMF) in advanced squamous cell carcinoma of the uterine cervix (SCC). This phase II trial sought to determine the efficacy and toxicities of NMF in patients with advanced SCC. Patients and methods: Eligibility for this trial required bidimensionally measurable squamous or adenosquamous cell cancer of the uterine cervix incurable by surgery or radiation therapy, ECOG performance status of ≤2, no prior NMF and no more than one prior chemotherapy regimen. Patients received NMF at 2000 mg/m 2 intravenously over 15-30 minutes days 1, 8 and 15. The cycle was repeated every 42 days. A single dose escalation of 25%, 500 mg/m 2 was made after the first cycle if the toxicities did not exceed grade I for hepatic toxicity and grade II for nausea and vomiting. Results: From July 1987 through September 1998, 21 patients with advanced squamous cell carcinoma of the uterine cervix were entered on study. Two patients were ineligible because there was no pretreatment SGOT on one and the other deteriorated prior to drug approval. Therefore, 19 patients were include in the analysis of response and survival. Four were inevaluable, three due to inappropriate tumor evaluation and one secondary to grade III vomiting, who went off study. These patients were included in the denominator while computing the results. There were 2 deaths, one due to pulmonary hemorrhage from perforation during central venous insertion and one due to disease. 30% (6/19) patients had toxicities, Eastern Cooperative Oncology Group (ECOG) grade III or higher and 2 of these patients suffered multiple grade III toxicities. There were no complete or partial responses. Conclusion: In this population, NMF in the dose and schedule employed exhibited no clinical activity.
KW - N-Methylformamide
KW - Squamous cell carcinoma
KW - Uterine cervix
UR - http://www.scopus.com/inward/record.url?scp=0034844521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034844521&partnerID=8YFLogxK
U2 - 10.1023/A:1010672618269
DO - 10.1023/A:1010672618269
M3 - Article
C2 - 11561680
AN - SCOPUS:0034844521
SN - 0167-6997
VL - 19
SP - 233
EP - 237
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 3
ER -